The frequencies of IDH1 and IDH2 mutations are higher in cytogenetically normal (CN) versus abnormal AML patients (11 versus 3.5% for IDH1 mutations; and 16 versus 3.8% for IDH2 mutations), placing them among the most common molecular aberrations in CN-AML. The gene discussed is IDH2; the disease is acute myeloid leukemia.